
Feature|Articles|July 7, 2026
Curbing Cognitive Decline in Epilepsy: Introducing Cleveland Clinic’s New HAP-E Pilot Program
Author(s)Marco Meglio
Fact checked by: Nicole Canfora Lupo
Cleveland Clinic pilots HAP-E, guiding older adults to manage epilepsy and cognitive decline with lifestyle tools, medication support, and virtual access.
Advertisement
Advertisement
As the global population ages, epilepsy is becoming one of the most common, and most overlooked, neurological conditions of later life: People with epilepsy face nearly triple the risk of developing dementia, dementia patients face a 5- to 10-fold increased risk of developing epilepsy, and older adults now account for roughly a quarter of all first-time seizures.1 Despite the prevalence, few centers are dedicated to the care of patients facing the unique challenges that come with epilepsy in later years of life, including these difficult-to-treat coexisting conditions.
Related to this article

Carlos Cruchaga, PhD, director of the NeuroGenomics and Informatics Center at Washington University, discusses emerging blood-based biomarkers for monitoring biological and cognitive responses to lecanemab treatment in Alzheimer disease.

At a NeurologyLive Clinical Forum in Philadelphia, Jessica D. Schulte, MD, PhD, of NYU Grossman School of Medicine, discussed how earlier recognition and systemic therapy options are changing the treatment paradigm for patients with NF1-associated plexiform neurofibromas.

Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.

An MDS 2026 plenary speaker discusses the evolving role of infusion therapies, deep brain stimulation, and focused ultrasound in Parkinson disease, including when to consider device-aided therapies and how treatment selection can be individualized.

The associate vice president of clinical research at the Parkinson's Foundation discussed a large-scale replication of rs3115534-G, a noncoding GBA1 variant tied to Parkinson disease in people of African ancestry.

Benjamin Walter, MD, MBA, discusses how advances in biomarker testing and genetic characterization are informing Parkinson disease care, alongside developments in adaptive deep brain stimulation and efforts to identify disease earlier.
Advertisement
Advertisement


